Plenary Session
Podcast autorstwa Vinay Prasad, MD MPH

Kategorie:
397 Odcinki
-
5.06 - POLO trial now has OS results - OMG
Opublikowany: 21.07.2022 -
5.05 - Citations, Metrics, Rankings in Oncology & Medicine
Opublikowany: 18.07.2022 -
5.04 - Echelon 1 reports OS benefit - But does it add up?
Opublikowany: 14.07.2022 -
5.03 - VPs Grand Rounds Lecture - Evidence Based Medicine - Will it Survive?
Opublikowany: 13.07.2022 -
5.02 - Listener Questions - Cancer & Evidence Philosophy - What this Pod Offers
Opublikowany: 11.07.2022 -
5.01 - How To Read Randomized Trials In Cancer
Opublikowany: 7.07.2022 -
Lies and Exaggerations about Kids Vaccines < 5 years Old is Bad Public Health
Opublikowany: 22.06.2022 -
Enact Trial - Enza vs Active Surveillance in Localized Prostate Cancer
Opublikowany: 20.06.2022 -
Kids Vaccine For Under 5 years Old
Opublikowany: 18.06.2022 -
H. Jack West; Lung Cancer; Podcasting; TeleHealth: PACIFIC; ADAURA;CM816: KN189
Opublikowany: 18.06.2022 -
QuANTUM - Quizartinib Front Line - Ethics of Global Trials
Opublikowany: 15.06.2022 -
4.67 Teclistimab for R/R Multiple Myeloma
Opublikowany: 9.06.2022 -
4.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate??
Opublikowany: 8.06.2022 -
4.65 DESTINY BREAST 04 - A complex trial to deconstruct
Opublikowany: 7.06.2022 -
4.64 - DETERMINATION - Should we still use transplant Myeloma?
Opublikowany: 6.06.2022 -
4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer
Opublikowany: 5.06.2022 -
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
Opublikowany: 4.06.2022 -
4.61 - How CDC's Vaccine Safety Missed Cases Of Myocarditis
Opublikowany: 27.05.2022 -
4.60 - NEW JCO paper - AML, EFS, CR, CRi, and Surrogate validation - FDA & Methods
Opublikowany: 21.05.2022 -
4.59 - How to be a better reader of case control studies
Opublikowany: 17.05.2022
A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California, San Francisco. Tweet your feedback to @Plenary_Session or e-mail [email protected].